First human doses of experimental drug BI 764198 tested for safety
NCT ID NCT03854552
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This early-stage trial tests the safety and tolerability of a new drug, BI 764198, in healthy men aged 18 to 45. Participants receive a single rising dose of the drug or a placebo. The study measures side effects and how the drug moves through the body, but does not aim to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BI 764198 (Apecotrep)
- What could go wrong
- This is an early Phase 1 safety study in healthy volunteers, not patients. It does not test any disease treatment, and the drug may never be developed further.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Which medical adhesive stays put longest without itching? a head-to-head test in healthy women.
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- New eye drop aims to tame ocular pain in early trial
- Could a formula closer to breast milk boost baby development?
- Could a daily probiotic help you feel fuller and eat less?